Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Executive Summary
Federal Circuit finds Patent Trial and Appeal Board was correct in deciding composition patent on antibiotic was not obvious; Pfizer's inter partes review petition challenging Alzheimer's-related patent ended in settlement.
You may also be interested in...
Patents Face 'Real Threat' From Inter Partes Review; PTAB Open To Change
Pfizer attorney says brand-name drug companies no longer can rely on the outcome of ANDA litigation to predict date of generic competition; PTAB chief judge observes that there is 'opportunity to get some more certainty for patent owners.'
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.
New Patent Battleground: Inter Partes Reviews Besiege Innovators
Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.